Aurobindo Pharma arm expands MSD pact, to set up $150-175 million facility

Aurobindo Pharma unit TheraNym expands CMO deal with MSD, to build 60,000 litre Unit 2 drug substance plant investing $150 to $175 million, stock gains 2.63%.

Leave a Reply

Your email address will not be published. Required fields are marked *